Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008

"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."

Trial Locations (2)

66034

Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, Via S. Spaventa, 37, Lanciano

Unknown

Dipartimento di Medicina e Scienze dell'Invecchiamento, Chieti

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY